McMaster University and Juravinski Hospital and Cancer Centre, Hamilton, ON.
McGill University and Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC.
Curr Oncol. 2020 Oct;27(5):270-274. doi: 10.3747/co.27.7149. Epub 2020 Oct 1.
The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 has necessitated changes to the way patients with chronic diseases are managed. Given that patients with multiple myeloma are at increased risk of covid-19 infection and related complications, national bodies and experts around the globe have made recommendations for risk mitigation strategies for those vulnerable patients. Understandably, because of the novelty of the virus, many of the proposed risk mitigation strategies have thus far been reactionary and cannot be supported by strong evidence. In this editorial, we highlight some of the risk mitigation strategies implemented at our institutions across Canada during the first wave of covid-19, and we discuss the considerations that should be made when managing patients during the second wave and beyond.
由新型严重急性呼吸系统综合症冠状病毒 2 引起的 2019 年冠状病毒病（covid-19）大流行，使得慢性病患者的管理方式发生了变化。由于多发性骨髓瘤患者感染 covid-19 及相关并发症的风险增加，全球各国机构和专家针对这些脆弱患者提出了降低风险的策略建议。可以理解的是，由于该病毒具有新颖性，因此迄今为止提出的许多降低风险的策略都是反应性的，并且无法得到强有力的证据支持。在本社论中，我们重点介绍了加拿大各地各机构在 covid-19 第一波疫情期间实施的一些降低风险的策略，并讨论了在第二波疫情及以后管理患者时应考虑的因素。
